Suppr超能文献

Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.

作者信息

Schröder Martin, Renatus Martin, Liang Xiaoyou, Meili Fabian, Zoller Thomas, Ferrand Sandrine, Gauter Francois, Li Xiaoyan, Sigoillot Frederic, Gleim Scott, Stachyra Therese-Marie, Thomas Jason R, Begue Damien, Khoshouei Maryam, Lefeuvre Peggy, Andraos-Rey Rita, Chung BoYee, Ma Renate, Pinch Benika, Hofmann Andreas, Schirle Markus, Schmiedeberg Niko, Imbach Patricia, Gorses Delphine, Calkins Keith, Bauer-Probst Beatrice, Maschlej Magdalena, Niederst Matt, Maher Rob, Henault Martin, Alford John, Ahrne Erik, Tordella Luca, Hollingworth Greg, Thomä Nicolas H, Vulpetti Anna, Radimerski Thomas, Holzer Philipp, Carbonneau Seth, Thoma Claudio R

机构信息

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Ridgeline Discovery, Basel, Switzerland.

出版信息

Nat Commun. 2024 Aug 19;15(1):7109. doi: 10.1038/s41467-024-51317-6.

DOI:10.1038/s41467-024-51317-6
PMID:39160182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11333602/
Abstract
摘要

相似文献

1
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.作者更正：基于DCAF1的PROTACs对临床验证靶点具有活性，克服内在和获得性降解抗性。
Nat Commun. 2024 Aug 19;15(1):7109. doi: 10.1038/s41467-024-51317-6.
2
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.基于 DCAF1 的 PROTACs 对经过临床验证的靶点具有活性，可克服内在和获得性降解剂耐药性。
Nat Commun. 2024 Jan 4;15(1):275. doi: 10.1038/s41467-023-44237-4.
3
What influences the activity of Degrader-Antibody conjugates (DACs).是什么影响了降解剂-抗体偶联物（DACs）的活性。
Eur J Med Chem. 2024 Mar 15;268:116216. doi: 10.1016/j.ejmech.2024.116216. Epub 2024 Feb 3.
4
Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.DCAF1-PROTAC-WDR5 三元复合物的晶体结构为 DCAF1 底物特异性提供了深入了解。
Nat Commun. 2024 Nov 23;15(1):10165. doi: 10.1038/s41467-024-54500-x.
5
Major Advances in Emerging Degrader Technologies.新兴降解技术的重大进展
Front Cell Dev Biol. 2022 Jun 22;10:921958. doi: 10.3389/fcell.2022.921958. eCollection 2022.
6
Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs.雌激素受体-α靶向作用：PROTACs、SNIPERs、肽- PROTACs、抗体偶联PROTACs和SNIPERs。
Pharmaceutics. 2022 Nov 19;14(11):2523. doi: 10.3390/pharmaceutics14112523.
7
Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.发现一种用于靶向三阴性乳腺癌转录调控的强效、选择性且口服生物可利用的CDK9降解剂。
Bioorg Chem. 2024 Dec;153:107876. doi: 10.1016/j.bioorg.2024.107876. Epub 2024 Oct 9.
8
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment.表观遗传疗法与靶向蛋白质降解相结合：癌症治疗中的组蛋白去乙酰化酶-蛋白酶体靶向嵌合体
Future Med Chem. 2025 Jul 16:1-13. doi: 10.1080/17568919.2025.2533113.
9
Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors.发现一种新型口服生物可利用的 FLT3-PROTAC 降解剂，可有效治疗急性髓系白血病并克服 FLT3 抑制剂的耐药性。
J Med Chem. 2024 May 9;67(9):7197-7223. doi: 10.1021/acs.jmedchem.4c00051. Epub 2024 Apr 24.
10
Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation.推进脑肿瘤治疗：揭示PROTACs靶向蛋白降解的潜力。
Cytotechnology. 2025 Apr;77(2):54. doi: 10.1007/s10616-025-00716-8. Epub 2025 Jan 31.

引用本文的文献

1
Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.揭示基于三唑并喹喔啉的新型PROTAC，其设计用于选择性降解ncBAF染色质重塑亚基BRD9。
Chemistry. 2025 Jun 17;31(34):e202404218. doi: 10.1002/chem.202404218. Epub 2025 May 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验